New hope for teens with stubborn hives: drug trial launches

NCT ID NCT05677451

Ongoing Disease control Sponsor: Novartis Pharmaceuticals Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jul 21, 2026 · Updated 2 times

Summary

This study tests a drug called remibrutinib in teenagers aged 12 to 17 who have chronic spontaneous urticaria (hives that come and go for no clear reason) that isn't controlled by antihistamines. About 100 participants will receive either the drug or a placebo for 24 weeks, with an option to continue treatment for up to 3 more years. The goal is to see if the drug reduces itching and hives better than a placebo.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: remibrutinib (a drug that targets inflammation to reduce hives and itching)
What this could lead to: If it works, this could provide a new treatment option for teenagers with chronic hives that don't respond to standard antihistamines.
What could go wrong: This is a Phase 3 trial, but it's still early for this age group. The drug may not work better than placebo, and side effects are possible. Long-term safety is still being studied.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

chronic idiopathic urticaria Chronic Urticaria

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CHRONIC SPONTANEOUS URTICARIA

Contacts and locations

Locations

Allergy Associates of Utah

Sandy City, Utah, 84093, United States
Allergy Asthma and Clinical Research

Oklahoma City, Oklahoma, 73120, United States
Allergy and Asthma Medical Group and Research Center

San Diego, California, 92123, United States
Allergy and Asthma Specialist P S C

Owensboro, Kentucky, 42301, United States
Allergy and Clinical Immunology Associates

Pittsburgh, Pennsylvania, 15241, United States
Endeavor Health

Glenview, Illinois, 60077, United States
Kern Research

Bakersfield, California, 93301, United States
Novartis Investigative Site

CABA, Buenos Aires, C1414AIF, Argentina
Novartis Investigative Site

Rosario, Santa Fe Province, 2000, Argentina
Novartis Investigative Site

CABA, C1181ACH, Argentina
Novartis Investigative Site

San Miguel de Tucumán, T4000AXL, Argentina
Novartis Investigative Site

Montreal, Quebec, H4A 3J1, Canada
Novartis Investigative Site

Santiago, Santiago Metropolitan, 8420383, Chile
Novartis Investigative Site

Guangzhou, Guangdong, 510091, China
Novartis Investigative Site

Chengdu, Sichuan, 610041, China
Novartis Investigative Site

Beijing, 100050, China
Novartis Investigative Site

Beijing, 100069, China
Novartis Investigative Site

Frankfurt am Main, Hesse, 60590, Germany
Novartis Investigative Site

Berlin, 13353, Germany
Novartis Investigative Site

Tübingen, 72076, Germany
Novartis Investigative Site

Hong Kong, Hong Kong, 999077, Hong Kong
Novartis Investigative Site

Hong Kong, 999077, Hong Kong
Novartis Investigative Site

Florence, FI, 50139, Italy
Novartis Investigative Site

Pavia, PV, 27100, Italy
Novartis Investigative Site

Siena, SI, 53100, Italy
Novartis Investigative Site

Kitakyushu, Fukuoka, 8078556, Japan
Novartis Investigative Site

Kamimashi-gun, Kumamoto, 861-3106, Japan
Novartis Investigative Site

Sakai, Osaka, 5938324, Japan
Novartis Investigative Site

Izumo, Shimane, 6938501, Japan
Novartis Investigative Site

Itabashi-ku, Tokyo, 1738610, Japan
Novartis Investigative Site

Kuching, Sarawak, 93586, Malaysia
Novartis Investigative Site

Utrecht, 3584 CX, Netherlands
Novartis Investigative Site

Lodz, 90-436, Poland
Novartis Investigative Site

Pretoria, Gauteng, 0181, South Africa
Novartis Investigative Site

Cape Town, 7925, South Africa
Novartis Investigative Site

Esplugues, Barcelona, 08950, Spain
Novartis Investigative Site

Valencia, 46014, Spain
Novartis Investigative Site

Songkhla, Hat Yai, 90110, Thailand
Novartis Investigative Site

Bangkok, 10330, Thailand
Novartis Investigative Site

Bangkok, 10700, Thailand
Novartis Investigative Site

Istanbul, Fatih, 34093, Turkey (Türkiye)
Novartis Investigative Site

Ankara, Sihhiye-Altindag, 06230, Turkey (Türkiye)
Novartis Investigative Site

Adana, 01330, Turkey (Türkiye)
Novartis Investigative Site

Peterborough, Cambridgeshire, PE3 9GZ, United Kingdom
Novartis Investigative Site

Manchester, M13 9WL, United Kingdom
Novartis Investigative Site

Southampton, SO16 6YD, United Kingdom
Pediatric Dermatology of Miami at the Pediatric CoE

Miami, Florida, 33156, United States
RFSA Dermatology

San Antonio, Texas, 78213, United States
Toledo Institute of Clinical Research

Toledo, Ohio, 43617, United States
Treasure Valley Medical Research

Boise, Idaho, 83706, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.